AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BANGKOK, Feb 1 Asia Pulse - In a major breakthrough on the final days of the outgoing interim government, a giant pharmaceutical firm has agreed to provide a life-saving drug, Imatinib, free, to cancer patients under the universal healthcare scheme in exchange for Thailand opting to not issue compulsory licences on the drug, the outgoing Thai Public Health Minister said on Thursday.
Dr Mongkol Na Songkhla announced that Novartis (Thailand) and its regional headquarters said in its letter to the department that the company would provide Imatinib for patients suffering from leukaemia and gastrointestinal cancer without charge under the Glivec International Patient Assistance Programme-GIPAP). The free access to the life-saving drug will be given to those patients who have household income per year less than Bt 1.7 million (US$51,515). "Such a positive offer does not warrant the department to issue compulsory licensing for the drug," said the outgoing minister, adding that he would like other drug companies to take similar steps to avoid enforcement of the compulsory licensing option.
Describing the agreement as "win-win situation" which benefits the patients and the company, Dr Vichai Chokewiwat, advisor to the ...